Evaluation of the relationship between pharmacokinetics and the safety of aripiprazole and its cardiovascular effects in healthy volunteers
Entity
UAM. Departamento de FarmacologíaPublisher
Lippincott, Williams & WilkinsDate
2016-12-01Citation
10.1097/JCP.0000000000000577
Journal of Clinical Psychopharmacology 36.6 (2016): 608 – 614
ISSN
0271-0749 (print); 1533-712 (online)DOI
10.1097/JCP.0000000000000577Funded by
This study was partially funded by Fundación Teófilo Hernando and Foundation for Biomedical Research at Hospital Universitario de La PrincesaEditor's Version
http://dx.doi.org/10.1097/JCP.0000000000000577Subjects
aripiprazole; pharmacodynamics; pharmacokinetics; safety; Farmacia; MedicinaRights
© 2016 Wolters Kluwer Health, Inc. All rights reservedAbstract
The aim of this study was the evaluation of the possible relationship between pharmacokinetics and the safety of aripiprazole as well as its influence on blood pressure (BP), heart rate (HR), and corrected QT (QTc) interval. Methods: The study population comprised 157 healthy volunteers from 6 bioequivalence clinical trials. Subjects were administered a single 10-mg oral dose of each formulation separated by a 28-day washout period. Plasma concentrations were measured using high-performance liquid chromatography coupled to mass spectrometry. Blood pressure was measured at the following times: predose and 0.5, 2, 4, 6, and 8 hours postdose. An electrocardiogram was recorded at predose, 4, and 8 hours postdose. Results: Area under the curve (AUC), maximum plasma concentration, half-life, and distribution volume corrected for weight were higher in women. Aripiprazole treatment produced a decrease of BP (9.3 mm Hg on systolic and 6.2 mm Hg on diastolic pressure) and an increase in HR (12.1 beats per minute) and QTc interval (9.1 milliseconds). There were sex differences in BP, HR, and QTc interval. Women and subjects with higher AUC and maximum plasma concentration values were more prone to experience adverse drug reactions and gastrointestinal adverse reactions. The AUC was related with systolic BP and diastolic BP decrease and HR increase but there was no relationship between aripiprazole concentrations and QTc increase. Conclusions: Aripiprazole decreases BP and increases HR and QTc interval. Pharmacokinetics, pharmacodynamics, and safety of aripiprazole are affected by sex. There is a directly proportional relationship between pharmacokinetic parameters and adverse drug reactions and effect on BP and HR
Files in this item
Google Scholar:Belmonte, Carmen
-
Ochoa Mazarro, María Dolores
-
Román, Manuel
-
Cabaleiro, Teresa
-
Talegón, Maria
-
Sánchez-Rojas, Sergio Daniel
-
Abad Santos, Francisco
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
Hernández-Jiménez, Macarena; Martín-Vílchez, Samuel; Ochoa Mazarro, María Dolores; Mejía-Abril, Gina; Román, Manuel; Camargo-Mamani, Paola; Luquero-Bueno, Sergio; Jilma, Bernd; Moro, María A.; Fernández, Gerónimo; Piñeiro, David; Ribó, Marc; González, Víctor M.; Lizasoain, Ignacio; Abad Santos, Francisco
2022-06-01